Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mirum Pharmaceuticals Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners across 4 art units, creating a substantial and distributed prosecution workload. The examiner count is lower than the action count, so at least one examiner handles more than one pending matter.
GALSTER, SAMUEL LEONARD is the busiest examiner, with 2 pending matters. That is the only identified examiner concentration in the profile, making those matters a practical starting point for coordinated review. The remaining work requires tracking across the other examiner and art-unit assignments.
Counsel should organize response strategy by art unit and examiner, while looking for claim language or disclosure positions that can be consistently maintained across related matters. The data does not establish that the actions share identical grounds, so each response still requires record-specific analysis.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| Double-patenting + other | 5 (71%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 2 | 52.1% | +42.2% |
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| SHOWALTER, ALEXANDER KEITH | 1 | 55.4% | +27.3% |
| MCANANY, JOHN D | 1 | 65.1% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18368041 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | DAHLIN, HEATHER RAQUEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430125 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | GALSTER, SAMUEL LEONARD | 92d overdue |
| 18382636 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | SCHMIDT, IZABELA MARIA | — |
| 18368041 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | DAHLIN, HEATHER RAQUEL | — |
| 17981033 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | SZNAIDMAN, MARCOS L | — |
| 17972909 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | GALSTER, SAMUEL LEONARD | — |
| 17973194 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | SHOWALTER, ALEXANDER KEITH | — |
| 17430210 | METHODS FOR TREATING CHOLESTASIS | MCANANY, JOHN D | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1693 | 2 |
| 1621 | 1 |
| 1628 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18382636 | METHODS FOR TREATING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | SCHMIDT, IZABELA MARIA | 1621 | §102§103DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18368041 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | DAHLIN, HEATHER RAQUEL | 1629 | §102§112 | Final Rejection | — | Pending | Sep 14, 2023 |
| 17981033 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | SZNAIDMAN, MARCOS L | 1628 | §103DP | Final Rejection | — | Pending | Nov 04, 2022 |
| 17972909 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17973194 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17430125 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | GALSTER, SAMUEL LEONARD | 1693 | §103DP | Non-Final OA | 92d overdue | Pending | Aug 11, 2021 |
| 17430210 | METHODS FOR TREATING CHOLESTASIS | MCANANY, JOHN D | 1625 | §103DP | Final Rejection | — | Pending | Aug 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMirum Pharmaceuticals Inc. has 7 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Samuel Leonard Galster has the most, with 2 of Mirum Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
